ACADIA Pharmaceuticals Inc (ACAD)
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases in North America. Its marketed products include NUPLAZID (pimavanserin), used to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, a treatment for the symptoms of Rett syndrome. The company also maintains a development pipeline that includes remlifanserin, ACP-211, ACP-711, ACP-271, and ACP-2591, as well as the STOKE Antisense Oligonucleotide Program. ACADIA holds a license agreement with Neuren Pharmaceuticals for trofinetide and a collaboration agreement with Stoke Therapeutics for RNA-based medicines targeting severe neurodevelopmental diseases of the central nervous system. Founded in 1993 and formerly known as Receptor Technologies, Inc., the company is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACAD
|
$31.47
|
25.0% Upside
|
Undervalued
|
$32.80
|
30.3% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
11.4x
|
3.4x
|
3.9x
|
4.296 B
|
3.496 B
|
1.2%
|
74.3%
|
7.1
|
—
|
30.2%
|
